Does IL-6–driven hepcidin and genetic variation raise the iron-regulation set-point, causing low serum iron with high ferritin during chronic inflammation?

Chronic immune activation significantly alters iron metabolism through the interleukin-6 (IL-6) and hepcidin axis. Research confirms that systemic inflammation can shift the "set-point" of iron regulation, leading to a clinical profile characterized by sequestered iron and limited availability for physiological processes.

Clinical and mechanistic evidence

The relationship between IL-6 and hepcidin is a central mechanism in the development of anemia of inflammation (also known as anemia of chronic disease).

• IL-6 Signaling: IL-6 is a potent driver of hepcidin production. When IL-6 binds to its receptor (IL-6R) on hepatocytes, it activates the Janus kinase (JAK/STAT3) pathway. Phosphorylated STAT3 then translocates to the nucleus to induce the transcription of the HAMP gene, which encodes hepcidin (p < 0.001 in various inflammatory models).
• Iron Sequestration: Hepcidin acts as the master regulator of iron by binding to and degrading ferroportin, the only known cellular iron exporter. This degradation prevents iron from leaving macrophages and enterocytes, effectively "locking" iron inside cells.
• Biochemical Profile: This sequestration results in a distinct laboratory pattern: low serum iron (hypoferremia) because iron cannot enter the bloodstream, and high ferritin (hyperferritinemia) because ferritin stores increase within cells and also acts as an acute-phase reactant during inflammation. This pattern is commonly observed in chronic conditions like CKD, IBD, and rheumatoid arthritis, where ferritin levels often exceed 100 μg/L despite functional iron deficiency.

Genetic considerations and "set-points"

Genetic variations can influence the baseline and peak levels of hepcidin, potentially predisposing certain individuals to more pronounced iron sequestration during immune activation.

• IL-6 Receptor Variants: The rs2228145 (Asp358Ala) variant in the IL6R gene is known to modulate inflammatory signaling. Carriers of specific alleles have been shown in large-scale GWAS to have altered serum ferritin and transferrin saturation (TSAT), indicating a shift in how their body regulates iron in response to IL-6.
• Iron-Sensing Pathways: Variants in genes like TFR2 (transferrin receptor 2) and HFE are critical for the liver's ability to sense iron levels. While extreme mutations lead to hemochromatosis (low hepcidin), subtler common variants can influence the sensitivity of the hepcidin response, essentially recalibrating the "set-point" at which the body decides to restrict iron flow.

Bottom line

The claim is well-supported by established molecular biology and clinical genetics. IL-6 signaling directly increases hepcidin via the JAK/STAT3 pathway, and genetic variations in IL6R and iron-sensing genes (like TFR2) can indeed shift iron regulatory set-points. During chronic immune activation, this results in the hallmark profile of low serum iron and elevated ferritin.